Our findings that docetaxel alone or in combination is effective in TNBC PDXs from patients without gBRCA1/PALB2 mutations (by large, the most frequent subgroup of TNBC breast cancer) are coincident with other PDX literature studies. Here, PALB2 is linked to breast cancer.